ArticleKorean journal of urology2010
Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder.
Article in Korean journal of urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.BMC women's health · 2024Pooled it
- The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.International urology and nephrology · 2014Pooled it
- Clinical CYP2D6-Mediated Pharmacokinetic Drug-Drug Interactions of DA-8010 with Paroxetine or Mirabegron in Healthy Korean Participants.Drug design, development and therapy · 2026Article
- Immunohistochemical study of Rho-kinase pathway expression in a mouse model of prostate hypertrophy for preliminary study of progressive prostate cancer model establishment.Translational andrology and urology · 2025Article
- Hypoxia-Dependent Upregulation of VEGF Relies on β3-Adrenoceptor Signaling in Human Retinal Endothelial and Müller Cells.International journal of molecular sciences · 2025Article
- Detrusor Underactivity in Men with Bladder Outlet Obstruction.Biomedicines · 2022Review
- Urothelial Calcium-Sensing Receptor Modulates Micturition Function via Mediating Detrusor Activity and Ameliorates Bladder Hyperactivity in Rats.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.Cell communication and signaling : CCS · 2021Review
- Effects of combined treatment with fesoterodine and mirabegron in a pelvic congestion rat model: Results from in vitro and in vivo functional studies.Lower urinary tract symptoms · 2020Article
- Voiding Disorders in Pediatrician's Practice.Clinical medicine insights. Pediatrics · 2020Review
- Nanotechnology advances towards development of targeted-treatment for obesity.Journal of nanobiotechnology · 2019Review
- Effect of co-administration of BRL-37344 and tadalafil on reduction of overactive bladder symptoms after induction of detrusor overactivity in mice1.Acta cirurgica brasileira · 2019Article
- Respiratory dysfunction following initiation of mirabegron: A case report.Respiratory medicine case reports · 2019Article
- On the Site and Mechanism of Action of βInternational neurourology journal · 2017Review
- Caffeine as a Probable Factor for Increased Risk of OAB Development in Elderly People.Current urology · 2016Article
- Clinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndrome.Therapeutic advances in urology · 2015Review
- Mirabegron: a Beta-3 agonist for overactive bladder.The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists · 2014Review
- Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient compliance.Therapeutic advances in urology · 2014Article
- Neural control of lower urinary tract and targets for pharmacological therapy.International urogynecology journal · 2014Review
- β3-adrenergic receptor activity modulates melanoma cell proliferation and survival through nitric oxide signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present review article, we present an overview of beta-adrenoceptor (β-AR) subtype expression at the mRNA and receptor protein levels in the human detrusor, the in vitro and in vivo bladder function of the β3-AR, the in vivo effect of β3-AR agonists on detrusor overactivity in animal models, and the available results of clinical trials of β3-AR agonists for treating overactive bladder (OAB). There is a predominant expression of β3-AR mRNA in human bladder, constituting 97% of total β-AR mRNA. Also, functionally, the relaxant response of human detrusor to catecholamines is mainly mediated through the β3-ARs. Moreover, the presence of β1-, β2-, and β3-AR mRNAs in the urothelium and suburothelial layer of human bladder has been identified. Stimulation of urothelial β-ARs results in the release of nitric oxide and an unknown substance inhibiting detrusor contractions from the urothelium. Intravenous application of CL316,243, a selective β3-AR agonist, in rats selectively inhibits mechano-sensitive Aδ-fiber activity of the primary bladder afferents. A number of selective β3-AR agonists are currently being evaluated in clinical trials for OAB with promising preliminary results. In conclusion, the β3-AR agonists are the most notable alternative class of agents to antimuscarinics in the pharmacological treatment of OAB. The β3-AR agonists act to facilitate bladder storage function probably through at least two mechanisms: first, direct inhibition of the detrusor, and second, inhibition of bladder afferent neurotransduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.